Aspirin resistance (Q28195157)

Platelets and anti-platelet therapy.

Europe PubMed Central

title

Aspirin resistance (English)

0 references

1 reference

John W Eikelboom

2

0 references

Graeme J. Hankey

object named as

Graeme J Hankey

series ordinal

1

0 references

language of work or name

English

0 references

publication date

18 February 2006

0 references

published in

The Lancet

0 references

volume

367

0 references

issue

9510

0 references

page(s)

606-17

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Acetylation of prostaglandin synthase by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Inhibition of platelet prostaglandin synthetase by oral aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Platelet function assays

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Progress in the assessment of platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Platelet function testing in cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin resistance: definition, mechanisms and clinical read-outs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Cyclooxygenases-1 and −2 of Endothelial Cells Utilize Exogenous or Endogenous Arachidonic Acid for Transcellular Production of Thromboxane

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin Dosage and Thromboxane Synthesis in Patients with Vascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Platelet aggregation studies in coronary artery disease. Past 4. Effect of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Hypertension—time to move on

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin resistance: more than just a laboratory curiosity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

1 reference

7 January 2021

Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Variability in response to aspirin: do we understand the clinical relevance?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Narrative review: aspirin resistance and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Towards a definition of aspirin resistance: a typological approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin in cardiovascular disorders. What is the optimum dose?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Low-dose aspirin increases aspirin resistance in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Clinical pharmacokinetics of the salicylates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Clinical significance of esterases in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Effect of ibuprofen on cardioprotective effect of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Is the antiplatelet effect of aspirin affected by systemic inflammation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Isoprostane formation and inhibition in atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Modulation of oxidant stress in vivo in chronic cigarette smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Cigarette Smoking Acutely Increases Platelet Thrombus Formation in Patients With Coronary Artery Disease Taking Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Possible mechanisms of aspirin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Genetic variation in cyclooxygenase 1: effects on response to aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin resistance and genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin resistance and a single gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Genetic and environmental contributions to platelet aggregation: the Framingham heart study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

1 reference

7 January 2021

Development of aspirin resistance in persons with previous ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

From randomised trials to rational practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Inheritance and drug response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Pharmacogenomics--drug disposition, drug targets, and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968040-9

7 January 2021

10.1016/S0140-6736(06)68040-9

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16488805

1 reference

Consolidated OpenCitations Corpus – April 2017